ClinicalTrials.gov
ClinicalTrials.gov Menu

Factors That Influence Compliance With Disease-Modifying Therapy in Multiple Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00223457
Recruitment Status : Completed
First Posted : September 22, 2005
Last Update Posted : January 25, 2007
Sponsor:
Collaborator:
Biogen
Information provided by:
University of Texas Southwestern Medical Center

Brief Summary:
The purpose of this study is to evaluate the coorelation between patient factors, health care provider factors, drug factors and compliance in patients with relapsing forms of multiple sclerosis (RMS) treated with Disease Modifying Agents (DMA). We hypothesize that a number of factors influence compliance with DMA's.

Condition or disease Intervention/treatment
Multiple Sclerosis Behavioral: Factors that influence compliance

  Show Detailed Description

Study Type : Observational
Enrollment : 1040 participants
Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Cross-Sectional
Time Perspective: Retrospective
Official Title: Factors That Influence Compliance With Disease-Modifying Therapy in Multiple Sclerosis
Study Start Date : April 2004
Study Completion Date : September 2005

Resource links provided by the National Library of Medicine

U.S. FDA Resources





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of relapsing form of multiple sclerosis
  • Age 18 or older
  • Therapy with disease modifying agent (Glatiramer acetate, Interferon Beta-1b, ot Interferon Beta 1a (IM or SC) for at least 6 months
  • Access to the internet to complete the study survey

Exclusion Criteria:

  • Diagnosis of progressive forms of multiple sclerosis
  • Therapy on DMA for less than 6 months
  • Inability to complete the survey
  • Participation in other investigational studies within the last 6 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00223457


Locations
United States, Texas
UT Southwestern Medical Center
Dallas, Texas, United States, 75390
Sponsors and Collaborators
University of Texas Southwestern Medical Center
Biogen
Investigators
Principal Investigator: Elliot M Frohman, MD, PhD University of Texas, Southwestern Medical Center at Dallas
Principal Investigator: Katherine D Treadaway, LCSW UT Southwestern Medical Center

Publications of Results:
Other Publications:
ClinicalTrials.gov Identifier: NCT00223457     History of Changes
Other Study ID Numbers: MS DMA Compliance
First Posted: September 22, 2005    Key Record Dates
Last Update Posted: January 25, 2007
Last Verified: April 2005

Keywords provided by University of Texas Southwestern Medical Center:
multiple sclerosis
compliance
adherence
disease modifying therapy
depression
hope
quality of life

Additional relevant MeSH terms:
Sclerosis
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases